To see the other types of publications on this topic, follow the link: Biotech pharmaceutical industry.
Journal articles on the topic 'Biotech pharmaceutical industry'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Biotech pharmaceutical industry.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
BAUM, RUDY M. "Biotech Industry Moving Pharmaceutical Products to Market." Chemical & Engineering News 65, no. 29 (1987): 11–32. http://dx.doi.org/10.1021/cen-v065n029.p011.
Full text
2
Itoh, Toshio. "Biotech Trends in the Japanese Pharmaceutical Industry." Nature Biotechnology 5, no. 8 (1987): 794–99. http://dx.doi.org/10.1038/nbt0887-794.
Full text
3
Galambos, Louis, and Jeffrey L. Sturchio. "Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation." Business History Review 72, no. 2 (1998): 250–78. http://dx.doi.org/10.2307/3116278.
Full textAbstract:
During the twentieth century, the pharmaceutical industry experienced a series of dramatic changes as developments in science and technology generated new opportunities for innovation. Each of these transitions forced existing firms to develop new capabilities. The authors examine the most recent such transition, the shift to molecular genetics and recombinant DNA technology (1970 to the present), and explain how and why this transformation differed from the previous ones in pharmaceuticals. Small biotech startups played an important role in this transition, and the large pharmaceutical firms that began to enter the field had to develop new strategies for innovation. Two major strategies were adopted by the early movers, all of which created various kinds of alliances with the small biotech businesses. By the mid-1990s, the leading pharmaceutical manufacturers had established significant capabilities in the new field, but they were continuing to work with specialized biotechs in order to innovate across a broad range of therapeutic categories.
4
Golec, Joseph, and John A. Vernon. "Financial risk of the Biotech Industry versus the Pharmaceutical Industry." Applied Health Economics and Health Policy 7, no. 3 (2009): 155–65. http://dx.doi.org/10.1007/bf03256149.
Full text
5
Domonkos, Dávid. "Uncertainty in innovation in the biotech-pharmaceutical industry." Periodica Polytechnica Social and Management Sciences 18, no. 1 (2010): 21. http://dx.doi.org/10.3311/pp.so.2010-1.03.
Full text
6
de Castro, Luiz A. B. "Partnering Brazilian biotech with the global pharmaceutical industry." Nature Biotechnology 29, no. 3 (2011): 210–11. http://dx.doi.org/10.1038/nbt.1801.
Full text
7
Fischette, Christine T. "What Does Big Pharma Want From Biotech?" Asia-Pacific Biotech News 08, no. 10 (2004): 552–67. http://dx.doi.org/10.1142/s0219030304000886.
Full textAbstract:
The article is about the challenges of the pharmaceutical industry and the need for partnership and alliances. It also talks about how bid pharmaceutical companies decides what it wants to invest in or who they want to collaborate with.
8
Wonglimpiyarat, Jarunee. "Biotech revolution: the impact of biotechnology on the pharmaceutical industry." International Journal of Technology, Policy and Management 8, no. 2 (2008): 182. http://dx.doi.org/10.1504/ijtpm.2008.017219.
Full text
9
Xu, Bixia. "Market differential evaluations of strategic alliances in the pharmaceutical/biotech industry." Journal of High Technology Management Research 17, no. 1 (2006): 43–52. http://dx.doi.org/10.1016/j.hitech.2006.05.004.
Full text
10
Petrova, T. A., K. O. Sidorov, Yu G. Il’yinova, and I. A. Narkevich. "Venture financing in the segment of pharmaceutical biotechnology in the Russian Federation." Medical Almanac, no. 2 (June 16, 2019): 35–39. http://dx.doi.org/10.21145/2499-9954-2019-2-35-39.
Full textAbstract:
One of the main directions of the pharmaceutical industry is the transition to the stage of commercialization of the results of intellectual activity and to the large-scale creation of global markets for new products and services. In recent years, the number of research conducted in the pharmaceutical industry has increased, and the most acute question is the active introduction of research results into mass production. The article provides an overview of the current state of venture financing in the biotechnology industry of the Russian Federation, as the most effective mechanism for financing promising applied research and, in particular, in the pharmaceutical biotechnology segment. The authors reviewed the main program documents affecting the development of biotechnology in Russia. The main venture funds that invest in pharmaceutical biotech companies are identified. The assortment portfolio of invested companies developed for the treatment of certain diseases was considered, and the main direction for the study was determined. The analysis of the funds that carry out the grant support of applied biotechnological research has been carried out. It allows to overcome the «sowing» stage of development of an innovative company and get initial research results. The main reasons for the slow development of venture capital investments in the biotech industry are identified and ways to overcome them are proposed.
11
Anghel, Ion, Marian Siminica, Mirela Cristea, Mirela Sichigea, and GraSiela Georgiana Noja. "Intellectual Capital and Financial Performance of Biotech Companies in the Pharmaceutical Industry." www.amfiteatrueconomic.ro 20, no. 49 (2018): 631. http://dx.doi.org/10.24818/ea/2018/49/631.
Full text
12
McCutchen, William W., and Paul M. Swamidass. "Motivations for strategic alliances in the pharmaceutical/biotech industry: Some new findings." Journal of High Technology Management Research 15, no. 2 (2004): 197–214. http://dx.doi.org/10.1016/j.hitech.2004.03.003.
Full text
13
Kontnik, Lewis T. "Manufacturer and Industry Responses to the Counterfeiting Challenge." Journal of Pharmacy Practice 19, no. 3 (2006): 140–45. http://dx.doi.org/10.1177/0897190006292940.
Full textAbstract:
The appearance of counterfeit products in the drug supply chain has created challenges for the health care industry, law enforcement, and especially pharmaceutical and biotech therapeutic drug manufacturers, many of whom did not fully appreciate this threat just 10 years ago. This article summarizes a number of issues faced by manufacturers of branded medicines today and suggests some approaches from a broad biopharmaceuticals point of view that can be used to manage this new threat.
14
Garzon-Vico, Antonio. "Learning From Failure and Learning from Success in the Pharmaceutical and Biotech Industry." Academy of Management Proceedings 2012, no. 1 (2012): 14594. http://dx.doi.org/10.5465/ambpp.2012.14594abstract.
Full text
15
Buck, Elizabeth, Mark Mulvihill, and Kenneth K. Iwata. "Pursuit of Personalized Anticancer Therapy: Leveraging Collaboration Between Academia and the Biotech/Pharmaceutical Industry." Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77, no. 4 (2010): 358–65. http://dx.doi.org/10.1002/msj.20195.
Full text
16
NIGRO, GIOVANNA LO, AZZURRA MORREALE, SERENA ROBBA, and PAOLO ROMA. "BIOPHARMACEUTICAL ALLIANCES AND COMPETITION: A REAL OPTIONS GAMES APPROACH." International Journal of Innovation Management 17, no. 06 (2013): 1340023. http://dx.doi.org/10.1142/s1363919613400239.
Full textAbstract:
The competitive landscape where pharmaceutical and biotechnology companies operate has changed radically due to a scientific/technological progress that has revolutionised the process by which drugs are developed. In fact, pharmaceutical industry more and more relies on advances in biochemistry and molecular biology. As a consequence, the number of partnerships between pharmaceutical and biotech firms has grown significantly. Research contributions addressing the biopharmaceutical alliances design have also focused on the optimal timing to sign a partnership. In this paper, we introduce and analyse the effect of competition in biotechnology industry by modelling the decisions of whether and when ally with a pharmaceutical company through a real options game. We find that the timing decisions depend on the level of the competition, synergies obtained through the alliance and contract terms offered by the pharmaceutical company as well. Also, we show that the first mover might not always pre-empt the follower in partnering with the pharmaceutical company.
17
Gaudillière, Jean-Paul. "The pharmaceutical industry in the biotech century: toward a history of science, technology and business?" Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 32, no. 1 (2001): 191–201. http://dx.doi.org/10.1016/s1369-8486(00)00004-2.
Full text
18
McCutchen, William W., N. A. Jr., and Paul M. Swamidass. "Explaining the differences in domestic and cross-boundary strategic alliances in the pharmaceutical/biotech industry." International Journal of Technology Management 15, no. 3/4/5 (1998): 490. http://dx.doi.org/10.1504/ijtm.1998.002618.
Full text
19
Timmins, Peter. "Industry update: the latest developments in the field of therapeutic delivery, April 2019." Therapeutic Delivery 10, no. 8 (2019): 469–79. http://dx.doi.org/10.4155/tde-2019-0035.
Full textAbstract:
April 2019 was perhaps remarkable for the amount of industry news about gene therapy, and notably the announcement by a global contract development and manufacturing organization, Catalent, that it was creating a capability in gene therapy product development and manufacturing through its acquisition of Paragon Bioservices, Inc (MD, USA). This move followed just a few weeks after another similar major contract development and manufacturing organization gene therapy acquisition. There was other encouraging gene and cell therapy news reported from AveXis (IL, USA), Ajinomoto Bio-Pharma (CA, USA), Kiadis Pharma (Amsterdam, The Netherlands), Fibrocell (PA, USA), Autolus Therapeutics plc (London, UK), ReNeuron (Surrey, England) and Kite Pharma (CA, USA). Also, there was plenty of therapeutic delivery technology innovation announced, including Calixar’s (Lyon, France) membrane protein stabilization drug discovery technology, the Eli Lilly (IN, USA)/Avidity Biosciences LLC (CA, USA) deal around antibody oligonucleotide conjugates, ViiV Healthcare’s regulatory filing for its long-acting anti-HIV-1 intramuscular injection, Marinomed Biotech’s (Vienna, Austria) solubilization technology and an EU approval filing for Novo Nordisk’s (Bagsværd, Denmark) oral delivery formulation of glucagon-like peptide-1 analog semaglutide. Diseases and treatment approaches that currently figure strongly in many biotech and big pharma pipelines and portfolios, notably nonalcoholic steatohepatitis and immuno-oncology, were as ever in the news, along with a number of rare disease therapies. As always, information sources employed to provide the materials used in compiling this update included company press releases, conference news and other news websites.
20
Backhaus, Kristin. "The Role of International, Technological and Social Context in Considering Strategic Alliances in the Biotech–Pharmaceutical Industry." Organization Management Journal 12, no. 3 (2015): 109. http://dx.doi.org/10.1080/15416518.2015.1087263.
Full text
21
Miyashige, Tetsuya. "Analysis of R&D efficiency of new biopharmaceuticals based on large-scale quantitative analysis and careful case analysis." Impact 2021, no. 2 (2021): 59–61. http://dx.doi.org/10.21820/23987073.2021.2.59.
Full textAbstract:
Research on the R&D efficiency of new biopharmaceuticals is geared towards enhancing efficiencies, such as improving drug development technologies and therefore speeding up the discovery and development of new treatments. Organisation theory is one way of exploring R&D efficiency and involves studying the behaviour of organisations with a view to enhancing organisational efficiency. Professor Tetsuya Miyashige and his team at the National Institute of Technology, Toyama College, Japan, are using large-scale quantitative analysis and careful case analysis to analyse the R&D efficiency of new pharmaceuticals. The goal is to contribute to the R&D management of pharmaceutical companies and to industrial economic policy for the pharmaceutical industry. A particular focus for the researcher is using biotechnology to analyse the R&D efficiency of 'antibody drug = biomedicine' in pharmaceutical companies. In collaboration with econometrician Professor Atsushi Fujii, University of Kitakyushu, Miyashige worked on the separation of R&D processes in biopharmaceutical R&D. This work involved analysing the R&D productivity of a biopharmaceutical company, with a focus on separation of the R&D processes and looking at blockbusters and biotech drugs. Another line of work involved empirically analysing the differences between blockbuster production in Japanese firms and in US/EU firms.
22
Miyashige, Tetsuya. "Analysis of R&D efficiency of new biopharmaceuticals based on large-scale quantitative analysis and careful case analysis." Impact 2021, no. 5 (2021): 19–21. http://dx.doi.org/10.21820/23987073.2021.5.19.
Full textAbstract:
Research on the R&D efficiency of new biopharmaceuticals is geared towards enhancing efficiencies, such as improving drug development technologies and therefore speeding up the discovery and development of new treatments. Organisation theory is one way of exploring R&D efficiency and involves studying the behaviour of organisations with a view to enhancing organisational efficiency. Professor Tetsuya Miyashige and his team at the National Institute of Technology, Toyama College, Japan, are using large-scale quantitative analysis and careful case analysis to analyse the R&D efficiency of new pharmaceuticals. The goal is to contribute to the R&D management of pharmaceutical companies and to industrial economic policy for the pharmaceutical industry. A particular focus for the researcher is using biotechnology to analyse the R&D efficiency of 'antibody drug = biomedicine' in pharmaceutical companies. In collaboration with econometrician Professor Atsushi Fujii, University of Kitakyushu, Miyashige worked on the separation of R&D processes in biopharmaceutical R&D. This work involved analysing the R&D productivity of a biopharmaceutical company, with a focus on separation of the R&D processes and looking at blockbusters and biotech drugs. Another line of work involved empirically analysing the differences between blockbuster production in Japanese firms and in US/EU firms.
23
Rossi, Matteo, Alkis Thrassou, and Demetris Vrontis. "Biotechnological mergers and acquisitions: features, trends and new dynamics." Journal of Research in Marketing and Entrepreneurship 17, no. 1 (2015): 91–109. http://dx.doi.org/10.1108/jrme-07-2014-0013.
Full textAbstract:
Purpose – The purpose of this paper is to analyze the phenomenon of mergers and acquisition (M & A) in high-tech sectors with a special focus on biotechnological firms. Recent years have witnessed an impressive wave of M & As, but these operations, despite their popularity, have produced mixed results for their stakeholders and presented no systemic vision. Design/methodology/approach – The paper is descriptive and the result of a secondary data-based research. Methodologically founded on the works of Rossi et al. (2011, 2013) and following an extensive literature review on M & A processes in high-tech sectors, the paper analyzes the dynamics, trends and attributes biotechnological M & As. Findings – The biotechnology sector, over the economically turbulent past few years, faced a distinct difficulty in attracting significant investor capital. Traditional pharmaceutical companies with sufficient cash from their existing sales but facing a dried-out product and patent pipeline have acquired innovative, but cash-poor biotech firms. The findings indicate that the trends in the biotech industry make consolidation in this sector inevitable. For acquiring firms, therefore, it will be necessary to realize a rigorous process of strategic target identification, due diligence and unified post-merger integration as the only way to create a sustainable shareholder value and high firm performance. Research limitations/implications – The limitations of the paper are a consequence of its very nature, i.e. the fact that it is a descriptive, secondary data-based research. Further, empirical research is therefore necessary to test the findings, to refine the contextual parameters involved and to prescribe target-specific action. Originality/value – The value of the paper stems from its definition of the link between the biotech industry attributes and M & A activities, consequently offering a valuable theoretical basis for empirical development and practical application, as well as a context for prescribed actions and processes.
24
Wang, Kung-Jeng, Yuliani Dwi Lestari, and Tsau-Tang Yang. "Location determinants of market expansion in China’s second-tier cities: a case study of the biotechnology industry." Journal of Business & Industrial Marketing 30, no. 2 (2015): 139–52. http://dx.doi.org/10.1108/jbim-03-2012-0048.
Full textAbstract:
Purpose – This study aims to examine the location determinants of market expansion of the biotechnology industry to China’s second-tier cities. Design/methodology/approach – The authors involved 68 top management officials of biopharmaceutical firms in China by applying triangulation data collection, which comprises depth interview, questionnaire survey and focus group discussion. Findings – Data collection results reveal the following: 20 location determinants are determined and categorized into 5 clusters (i.e. 3 cost/tax factors, 5 demand factors, 1 macroeconomic factor, 3 socio-political factors and 8 strategic factors); among these 20 factors, 9 factors contribute to firm benefits, 5 factors open opportunities for business growth and 6 factors pose potential risks. Originality/value – This study proposes a framework of location determinants for biotech pharmaceutical industry in expanding second-tier cities of China market. The findings of this study can be used as a reference for multinational companies, specifically in market expansion to second-tier cities in China.
25
Bruneau de la Salle, Margaux, and Mark Thomas. "Are M&As an opportunity for HR to join the top table? The case of Sanofi’s emerging international strategy." Strategic HR Review 20, no. 2 (2021): 66–70. http://dx.doi.org/10.1108/shr-01-2021-0007.
Full textAbstract:
Purpose One of major preoccupations of human resources (HR) in recent times has been the challenge of proving its value at the “top table.” Mergers and acquisitions (M&As) may offer one potential solution to this problem. M&As are renowned for the key management problems they generate such as diminished employee engagement and morale and increased staff turnover. However, such challenges also offer opportunities. This paper aims to argue that the recent wave of acquisitions in the pharmaceutical industry present HR with the possibility to demonstrate its real strategic value. Design/methodology/approach This paper offers an insider–outsider approach to the role of HR in M&As in the pharmaceutical industry. Based on an in-depth study of Sanofi’s emerging M&A strategy, it gives key insights into the reasons for multiple acquisitions and how HR can have a positive impact on value creation. Findings The findings demonstrate that the repeated acquisitions of US-based biotech companies made by the French pharmaceutical group Sanofi over the past five years is more than just a coincidence. Rather, it is an unstated strategy to develop within this market. HR can aid senior management in overcoming some of the major cultural challenges, thus demonstrating its real strategic value. Originality/value This paper clearly shows how following a specific emerging international strategy of M&As can empower a company through its human resources.
26
Papadopoulos, Vassilios, Dana Goldman, Clay Wang, Michele Keller, and Steven Chen. "Looking Ahead to 2030: Survey of Evolving Needs in Pharmacy Education." Pharmacy 9, no. 1 (2021): 59. http://dx.doi.org/10.3390/pharmacy9010059.
Full textAbstract:
In order to keep pharmacy education relevant to a rapidly-evolving future, this study sought to identify key insights from leaders from a broad array of pharmacy and non-pharmacy industries on the future of the pharmacy profession, pharmaceutical sciences, and pharmacy education. Thought leaders representing a variety of industries were surveyed regarding their perspectives on the future of pharmacy practice, pharmaceutical science disciplines, and pharmacy education in seven domains. From 46 completed surveys, top challenges/threats were barriers that limit clinical practice opportunities, excessive supply of pharmacists, and high drug costs. Major changes in the drug distribution system, automation/robotics, and new therapeutic approaches were identified as the top technological disrupters. Key drivers of pharmacy education included the primary care provider shortage, growing use of technology and data, and rising drug costs. The most significant sources of job growth outside of retail and hospital settings were managed care organizations, technology/biotech/pharmaceutical companies, and ambulatory care practices. Needs in the industry included clinical management of complex patients, leadership and management, pharmaceutical scientists, and implementation science. Knowledge gaps were pharmacists not recognizing their value on the health care team, preparation to embrace and lead change, and expertise in data science and analytics. Pharmacy schools will need to address several disruptive trends to future-proof their curricula, including expanding patient management skills, leadership and management training, technology, and data analytics.
27
Neel, Dylan, David Stephen Shulman, and Steven G. DuBois. "Sponsorship of pediatric oncology interventional trials." Journal of Clinical Oncology 37, no. 15_suppl (2019): 10044. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10044.
Full textAbstract:
10044 Background: The sponsor of a clinical trial is the single entity responsible for the overall conduct and oversight of the trial. Sponsors may be pharmaceutical/biotech companies (“industry”), government agencies (e.g. NIH), or other entities such as academic institutions. Trial sponsorship may have important regulatory and financial implications for the trial intervention under investigation. We sought to compare oncology trial sponsorship based upon age of eligibility. Methods: We used the clinicaltrials.gov database to evaluate all interventional trials from September 1, 2009 to December 1, 2018. We included all trials regardless of indication and then separately analyzed only oncology trials. We analyzed sponsor status as “industry”, “government”, or “other”. Results: Sponsorship data were available for 59,582 interventional trials across all disciplines (n = 15,564 oncology trials). Across all disciplines and ages of eligibility, lead trial sponsorship was 34% industry, 5% government, and 61% other. Across all oncology trials, sponsorship mix was similar: 31% industry; 6% government, and 62% other. Among adult oncology trials (age of eligibility starting at age 18 years), trial sponsorship was 33% industry, 6% government, and 61% other. Among pediatric-only oncology trials (age of eligibility capped < 18 years), trial sponsorship was 25% industry, 1% government, and 74% other. 5% of industry sponsored trials across all indications were pediatric-only compared to 0.63% of industry-sponsored trials in oncology. 95% of industry sponsored pediatric-only oncology trials were phase 1 or 2 trials, compared to 90% in adults. Conclusions: Pediatric-only interventional oncology trials are less likely to be industry sponsored compared to adult oncology trials or trials across all disciplines. Less than 1% of industry sponsored interventional trials in oncology focus on children < 18 years of age.
28
Lignou, Sapfo, and Ilina Singh. "Pharmaceutical industry, academia and people with experience of mental illness as partners in research: a need for ethical guidance." Wellcome Open Research 5 (August 20, 2020): 196. http://dx.doi.org/10.12688/wellcomeopenres.16166.1.
Full textAbstract:
Background: Several social and policy developments have led to research partnerships in mental health research, which depart from traditional research models. One form of such partnerships is among research institutions, industry (pharmaceutical and biotech) and people with lived experience of mental illness (RIPs). There are several benefits but also ethical challenges in RIPs. An ethics-based approach to anticipating and addressing such ethical issues in mental health research is lacking. Given the expansion of RIPs in treatment development for mental health illness, guidance to support ethical and trustworthy collaborative mental health research projects is essential. Methods: To develop a moral framework for evaluating the ethics of RIPs, we systematically searched PubMed for peer-reviewed literature discussing good practices in research partnerships. Searches were also conducted in websites of known organizations supporting patient engagement with industry in mental health research and in the references of short-listed articles. Following application of exclusion criteria, remaining articles were critically examined and summarised to synthesise principles for ethically acceptable RIPs and inform clear guidance and practices. Results: Critical analysis and synthesis of the short-listed articles highlighted the need for two sets of principles to guide ethical RIPs: principles for (a) RIPs as a trustworthy enterprise (e.g. public accountability, transparency) and (b) fair RIPs (e.g. effective governance, respect). We discuss the application of these principles in problem-solving strategies that can support best practice in establishing fair and successful mental health research partnerships among research institutions, industry and people with lived experience of mental illness. Conclusions: Ethical guidance is needed to prevent and address challenges in RIPs and to promote the scientific and social benefits of these new research partnership models in mental health research. We show how the proposed moral framework can guide research partners in designing, sustaining and assessing ethical and trustworthy collaborative mental health research projects.
29
Lignou, Sapfo, and Ilina Singh. "Pharmaceutical industry, academia and people with experience of mental illness as partners in research: a need for ethical guidance." Wellcome Open Research 5 (February 26, 2021): 196. http://dx.doi.org/10.12688/wellcomeopenres.16166.2.
Full textAbstract:
Background: Several social and policy developments have led to research partnerships in mental health research, which depart from traditional research models. One form of such partnerships is among Research institutions, Industry (pharmaceutical and biotech) and People with lived experience of mental illness (RIPs) in the NIHR services. There are several benefits but also challenges in such partnerships. An ethics-based approach to anticipating and addressing such problems is lacking. Given the expansion of RIPs in treatment development for mental health illness, guidance to support ethical and effective collaborations in NIHR-funded mental health research is essential. Methods: To develop a moral framework for evaluating the ethics of RIPs, we systematically searched PubMed for peer-reviewed literature discussing good practices in research partnerships. Searches were also conducted in websites of known organizations supporting patient engagement with industry in mental health research and in the references of short-listed articles. Following application of exclusion criteria, remaining articles were critically examined and summarised to synthesise principles for ethical RIPs and inform clear guidance and practices. Results: Critical analysis and synthesis of the short-listed articles highlighted the need for two sets of principles to guide ethical RIPs: principles for (a) RIPs as a trustworthy enterprise and (b) fair RIPs. We discuss the application of these principles in problem-solving strategies that can support best practice in establishing fair and effective research partnerships among research institutions, industry and people with lived experience of mental illness in the NIHR services. Conclusions: Ethical guidance is needed to prevent and address challenges in RIPs and to promote the scientific and social benefits of these new research partnership models in mental health research in the NIHR services. We show how the proposed moral framework can guide research partners in designing, sustaining and assessing ethical and effective mental health research collaborations.
30
Chitour, Hind Louiza. "Open innovation: An opportunity for Pharmerging countries to close the technology gap?" Journal on Innovation and Sustainability. RISUS ISSN 2179-3565 5, no. 1 (2014): 19. http://dx.doi.org/10.24212/2179-3565.2014v5i1p19-38.
Full textAbstract:
The pharmaceutical industry is entering a critical phase in its history, with decliningprofits and patent cliffs fallouts awaiting their former blockbuster drugs. Several hypotheseshave been formulated to explain the causes of this downfall whether it is the drought in theirR&D pipelines, the rising competition of generics or the ever-increasingpressure from healthcareproviders such as governments seeking to curb their health expenditures thus causing priceerosion. However, rather than striving to find the root causes of the issues the industry isfacing, the major players in the Pharma field should focus on implementing measures totransform the very structure of the pharmaceutical companies and change the drug discoveryand commercialization processes. These core changes that the pharmaceutical sector has toundergo could be achieved through several methods. One of the most suggested solutions tothis R&D bottleneck could be shifting from the traditional “closed model” towards a new “openinnovation” model based on collaboration of Pharma companies whether it includes workingtogether with a biotech company, CROs, Academia or local Pharma manufacturer. This openinnovation model is believed to foster innovation and invigorate the agonizing R&D Pharmasector as it proved itself to be effective resulting in innovative projects and ideas in the ITsector. It is in this context that this paper will address the opportunity emerging pharmaceuticalmarkets could benefit from when this open innovation model is applied to the pharmaceuticalindustry. Mainly, we will discuss the integration of this strategy within big Pharma companiesin their efforts to enter what is designated as “Pharmerging countries” in general with a specialfocus on one key global health market: China. We will discuss the impact of this innovationstrategy could bring in terms of both tangible and intangible benefits and potential drawbacks.
31
Lee, Yun-Huei. "APPLICATION OF A SWOT-FANP METHOD." Technological and Economic Development of Economy 19, no. 4 (2013): 570–92. http://dx.doi.org/10.3846/20294913.2013.837111.
Full textAbstract:
Strengths, weaknesses, opportunities, and threats (SWOT) analysis is an effective strategic planning tool for the development of strategy formulation, but its main weakness is being incapable of quantitatively determining the weights and effects of alternative strategic criteria. Some studies’ use of SWOT with analytic hierarchy process (AHP) would enable decision-makers to obtain-through pairwise comparisons-a relative priority of each criterion, so that the results from quantitative measures could overcome SWOT's central shortcoming. However, these studies neglect critical relationships or dependencies among SWOT factors. In this study, I propose a quantitative SWOT that rests on fuzzy analytic network process (FANP) methodology, includes possible dependencies among SWOT factors and permits the elimination of decision-makers’ uncertain and vague preferences. To this end, I chose the Taiwan biotech pharmaceutical industry as an illustrative example. This study demonstrates and validates that such an enhanced methodology is viable and highly capable of providing enriched insights regarding strategic decision-making management in complex real-world situations.
32
Collins, Tammy R. L., Kiri Hoff, Molly Starback, Patrick D. Brandt, Christopher E. Holmquist, and Rebekah L. Layton. "Creating and sustaining collaborative multi-institutional industry site visit programs: a toolkit." F1000Research 9 (November 12, 2020): 1317. http://dx.doi.org/10.12688/f1000research.26598.1.
Full textAbstract:
Background: As more early career scientists enter into diverse career pathways, visiting local companies or organizations can support their exploration of these paths. As an efficient way to facilitate this, we developed a collaborative regional site visit program: the Enhancing Local Industry Transitions through Exploration (ELITE) Consortium. Consortium members arrange half-day visits to local industry sites, thus providing companies and trainees the opportunity to meet and identify potential professional and career opportunities. Three different training institutions worked cooperatively in the development and maintenance of the program. The ELITE Consortium was developed with eight phased steps; guidelines and operating procedures were created for each of these steps and are provided along with sample materials for institutions interested in building similar programs. Methods: Prior to fully developing the program, trainee interests were evaluated via questionnaire. During program implementation and thereafter, program directors tracked attendance and collected career outcome data from publicly available sources to identify first job positions after training. Regression analyses and chi-squared analyses were used to examine site visit matches and career outcome data. Results: Analyses suggest a positive impact of site visits on postdoctoral and graduate trainees’ career outcomes at companies or institutions that match a similar sector (e.g., for-profit) and type (e.g., biotech, pharmaceutical, contract research organization). Despite a small sample size, evidence suggests an especially positive impact on trainees who organize site visits to companies compared with those who simply participate. Conclusions: The ELITE Consortium was successful in helping trainees explore and identify a multitude of career paths. Trainees attained employment either directly or in related companies and institutions visited by ELITE participants. The joint, three-institution, flexible nature of the ELITE Consortium positively impacts the program’s sustainability and reach. The toolkit provided here will help other institutions to replicate and adapt the program with minimal effort.
33
Roubou, I., and D. K. Alexopoulou. "The Various Shapes of Innovation." Forum of Clinical Oncology 6, no. 4 (2015): 12–22. http://dx.doi.org/10.1515/fco-2015-0019.
Full textAbstract:
Abstract Background: Innovation is one of the most difficult words to define, especially when it comes to health technology. The aim of this article is to get a better understanding of the multi-dimensional facet of innovation, how this is valued by different stakeholders and the way forward in order to create innovative interventions for the sake of the patients and the society. Methods: A literature search was performed using mainly the PubMed database and reports from various organisations (EFPIA, etc.). Results: In the past, innovation in the pharmaceutical industry was the result of the findings of basic science translated into clinical compounds, ending up in marketed drugs. This model is not valid anymore since significant changes reshaped the drivers of innovations and the key players. Rising costs, increased competition, new scientific and technological developments, well-informed patients created a much more challenging environment where coordinated and committed collaboration seemed to be the only way to overcome these obstacles and reach innovation in order to discover, develop and deliver medicines to patients. Conclusions: Innovation initiatives have already proved their value by providing solutions to the major challenges the industry faces. It is now clear that a healthy biomedical ecosystem is determined by all stakeholders-academia, nonprofit/for-profit research institutions, government agencies, pharma/biotech industry and patients. Innovation initiatives provide the platform needed in which all stakeholders can meet and share their knowledge in order to deliver through innovation improved outcomes for patients while shaping an efficient and sustainable healthcare system.
34
Han, Jian, Yonghong Xia, Lejun Lin, Zuoguang Zhang, Hui Tian, and Kefeng Li. "Next-generation Metabolomics in the Development of New Antidepressants: Using Albiflorin as an Example." Current Pharmaceutical Design 24, no. 22 (2018): 2530–40. http://dx.doi.org/10.2174/1381612824666180727114134.
Full textAbstract:
Depression is a highly prevalent disorder that affects more than 300 million adults worldwide in 2015. Depression also frequently coexists with many other conditions such as osteoporosis and one-third of the Intensive Care Unit (ICU) survivors had depressive symptoms. Antidepressants have become the most commonly prescribed drugs in the United States. In addition to the regular process, drug discovery and development (R&D) for depression presents extra challenges because of the heterogeneity of the symptoms and various co-occurring disorders. Botanical medicine with multi-functional nature has been proposed to be more effective, providing rapid control of core and comorbid conditions of depression. With the technical advances in analytical instruments, metabolomics is entering into a “new generation”. Next-generation metabolomics (NGM) has the capability to comprehensively characterize drug-induced metabolic changes in the biological systems. NGM has demonstrated great potential in all the stages of pharmaceutical R&D in the last 10 years. Albiflorin isolated from Peony roots is a promising drug candidate with multi-target for depression and is currently under development by Beijing Wonner Biotech. In this work, we summarized the common analytical platforms for NGM and its main applications in drug R&D. We used albiflorin as an example to illustrate how NGM improves our understanding of drug candidate actions and facilitates drug safety evaluation. Future directions on how to expand the use of NGM for new antidepressant development in pharmaceutical industry were also discussed.
35
Jäger, Stefan, Norbert Garbow, Achim Kirsch, et al. "A Modular, Fully Integrated Ultra-High-Throughput Screening System Based on Confocal Fluorescence Analysis Techniques." Journal of Biomolecular Screening 8, no. 6 (2003): 648–59. http://dx.doi.org/10.1177/1087057103258475.
Full textAbstract:
The rapid increase in size of compound libraries, as well as new targets emerging from the Human Genome Project, require progress in ultra-high-throughput screening (uHTS) systems. In a joint effort with scientists and engineers from the biotech and the pharmaceutical industry, a modular, fully integrated system for miniaturized uHTS was developed. The goal was to achieve high data quality in small assay volumes (1-4 μL) combined with reliable and unattended operation. Two new confocal fluorescence readers have been designed. One of the instruments is a 4-channel confocal fluorescence reader, measuring with 4 objectives in parallel. The fluorescence readout is based on single-molecule detection methods, allowing high sensitivity at low tracer concentrationsand delivering an information-rich output. The other instrument isa confocal fluorescence im aging reader, where the imagesare analyzed in terms of generic patternsand quantified in units of intensity per pixel. Both readers are spanning the application range from assays with isolated targets in homogenous solution or membrane vesiclebased assays (4-channel reader) to cell-based assays (imaging reader). Results from a comprehensive test on these assay types demonstrate the high quality and robustness of this screening system.
36
Chun, Young J., and Jeremy Honig. "This or That? Instructions for Use (IFU): IF U Could Pick Your Dream Printout Format." Proceedings of the Human Factors and Ergonomics Society Annual Meeting 64, no. 1 (2020): 1005–7. http://dx.doi.org/10.1177/1071181320641241.
Full textAbstract:
An Instructions for Use (IFU) is a critical element of a drug delivery device system user interface that is frequently used as risk mitigation when the product cannot be effectively mitigated by the design of the device itself. However, format of a printout IFU is often selected without thoughtful consideration or even neglected while the IFU contents such as wordings and images are iteratively improved over the course of device development. There is a limited number of research papers that exist on the effects of the IFU printout format on task performance, especially with a drug delivery device. This study was to evaluate two different IFU formats (spiral bound vs accordion style) on task performance for use of a complex reusable electromechanical injection pen device system for preparing and administering medication. This study provides valuable insights for biotech/pharmaceutical industry for optimizing their IFU design by selecting more appropriate hardcopy IFU format for their drug delivery device. This will enable creating optimal user experience as well as more effectively reducing use related risks as part of overall device user interface for a complex drug delivery device system.
37
Meldrum, Helen Mary. "Reflecting or ruminating: listening to the regrets of life science leaders." International Journal of Organization Theory & Behavior 24, no. 2 (2021): 77–92. http://dx.doi.org/10.1108/ijotb-06-2019-0069.
Full textAbstract:
PurposeThe overwhelming frequency of failure in trying to bring a safe and effective biotech, pharmaceutical or medical device product to market is truly astounding. This research synthesizes industry leaders' insights on lessons learned from reflecting on professional disappointments.Design/methodology/approachThis research used a qualitative approach to learning from the Chief Executive Officers (CEOs), Chief Scientific Officers (CSOs) and Chief Medical Officers (CMOs) of the most successful life science firms in the USA. A total of 45 industry leaders were interviewed regarding their lingering regrets about their career misadventures.FindingsRegrets were unavoidable because there were opportunity costs for every choice each leader made. Commentary about wisdom gained comprised themes regarding valuable time lost, strategies that could have been enacted, products that failed and essential personnel who were not managed optimally. Contrary to expectations, there was little mention of money that was squandered.Originality/valueNot felt as a solely negative emotion, regrets were recognized by these leaders as a potentially positive influence on their future decisions. Not felt as a solely negative emotion, regret was recognized by these leaders as a potentially positive influence on their future decisions. This exploratory study suggests that learning from retrospective and anticipated regrets benefits life science leaders in gaining clarity of thought regarding their current business challenges. Because prior research on the value of psychological regrets has mostly relied on limited samples, this inquiry contributes a new vantage point by examining a unique population of senior business leaders, thus providing broader applicability to the organizational literature.
38
Feola, Rosangela, Valentina Cucino, and Roberto Parente. "How to Develop Collaboration in Drug Development Process: The Role of Professional Service Firms." International Business Research 14, no. 4 (2021): 114. http://dx.doi.org/10.5539/ibr.v14n4p114.
Full textAbstract:
The innovation chain of the pharmaceutical industry is more and more complex.&nbsp; In particular, a new type of players, the start-ups founded by researchers (Academic Start-ups) have proven to be particularly effective in the first steps of exploring new, radically innovative technologies. These small start-ups miss the financial resources and the industrial experience necessary to embark in the later stage of technologies&rsquo; development. To overcome these limits, what academic start-ups require the most is a collaborative linkage with large biotech and pharma companies. To such end, Business Development Professionals are offering their services to academic start-ups, to set up a collaborative linkage with potential partners. Our article investigates the process of engagement between Academic Start-ups and Business Development Professionals and in particular, we focus on the factors that influence collaboration between the two actors. In order to investigate the development process of collaboration we conducted an exploratory study trough the submission of a semi-structured questionnaire covering different aspects of the engagement process to a sample of business professionals. The study provide first evidences about the main factors that prevent the development of collaborations and provides some suggestions to overcome the challenges that both parts found in the collaboration process.
39
Koenig, R. "Pharmaceuticals Industry: Giant Merger Creates Biotech Power." Science 271, no. 5255 (1996): 1490. http://dx.doi.org/10.1126/science.271.5255.1490.
Full text
40
NAN, Kaushalya, and Senarath WTPSK. "Callus Induction and In vitro Plantlet Regeneration of Gymnema sylvestre R. Br. (Retz.) and the Phytochemical Screening of Natural Plants and Callus Cultures." Plant Tissue Culture and Biotechnology 23, no. 2 (2014): 201–10. http://dx.doi.org/10.3329/ptcb.v23i2.17521.
Full textAbstract:
Gymnema sylvestre is a slow growing perennial medicinal woody climber. It belongs to the family Asclepiadaceae. Gymnemic acid, the major bioactive component of this plant species is used as a remedy for type II diabetes. Propagation of this plant is often difficult and expensive. In the present study, in vitro protocols were developed in order to induce callus and regenerate plantlets from different explants of G. sylverstre. As secondary metabolites are important in medicinal plants, studies were carried out to screen phytochemicals present in natural plants and callus. The best medium for callus induction from leaf discs was MS supplemented with 5.0 mg/l 2,4-D. Although, nodal segment grown in MS supplemented with 1.0 mg/l BA gave the highest shoot elongation (14.8 ± 0.20), growth regulator free MS also showed a high elongation of shoots (14.2 ± 0.37) and the difference between those two were non-significant. MS supplemented with 3.0 mg/l IBA was best for root induction. Highest survival percentage (62.5) was observed when plantlets were acclimated in a substrate containing a mixture of soil and sand in the proportion of 1 : 2. In the present study, phytochemicals present in callus and the leaves of the naturally grown plants were compared using Gas Chromatography- Mass Spectrophotometer. A total of nine compounds was identified from the leaves of naturally grown plants and nine compounds were identified from the callus. Out of all identified phytochemicals, a total of six compounds were present in both leaves and callus samples suggesting that in addition the plant material, callus may also be used as a supplement raw material to obtain secondary metabolites for the pharmaceutical industry. D. O. I. http://dx.doi.org/10.3329/ptcb.v23i2.17521 Plant Tissue Cult. & Biotech. 23(2): 201-210, 2013 (December)
41
Gottinger, Hans. "Organizational Entrepreneurship: A Historical Overview on Industry Alliances in Biotech and Pharmaceuticals." Open Business Journal 4, no. 1 (2011): 14–27. http://dx.doi.org/10.2174/1874915101104010014.
Full text
42
Triulzi, Giorgio, Andreas Pyka, and Ramon Scholz. "R&D and knowledge dynamics in university-industry relationships in biotech and pharmaceuticals: an agent-based model." International Journal of Biotechnology 13, no. 1/2/3 (2014): 137. http://dx.doi.org/10.1504/ijbt.2014.059650.
Full text
43
Grupp, Stephan A., Theodore W. Laetsch, Jochen Buechner, et al. "Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)." Blood 128, no. 22 (2016): 221. http://dx.doi.org/10.1182/blood.v128.22.221.221.
Full textAbstract:
Abstract A single-center trial of CD19 directed, lentiviral transduced chimeric antigen receptor (CAR) T cells (CTL019) for relapsed and refractory (r/r) B-ALL pediatric patients showed rates of CR >90% with prolonged CAR T cell persistence/CR without further therapy in the majority of patients infused (Maude NEJM 2014). We report here the feasibility, safety and efficacy of the first multicenter global pivotal registration CAR T cell trial. Features of this trial include: i) the first trial in which industry-manufactured cells were provided to all patients; ii) enrollment across 25 centers in the US, EU, Canada, Australia, and Japan; iii) successful transfer and manufacturing of cells in a global supply chain; and iv) successful implementation of cytokine release syndrome (CRS) management across a global trial. All patients had CD19 positive B-ALL with morphologic marrow tumor involvement at registration (>5% blasts), and were either primary refractory; chemo-refractory after first relapse, relapsed after second line therapy; or ineligible for allogeneic SCT. CTL019 was manufactured from patient PBMC under GMP conditions in the US, at a centralized "sponsor-owned" manufacturing facility, and supplied to all sites. The primary endpoint of overall remission rate (CR+CRi) within 3 months and secondary endpoints (EFS, DOR, OS and safety) were assessed by an independent review committee. Based on preliminary data as of March 2016, 57 patients were enrolled. There were 3 manufacturing failures (5%), 5 patients were not infused due to death or adverse events (9%), and 15 patients were pending infusion at the data cut off. Following fludarabine/cyclophosphamide lymphodepleting chemotherapy in the majority of the patients, 34 patients (median age 11 [3-23], 50% with prior HSCT) were infused with a single dose of CTL019 at a median dose of 2.9 x106 transduced CTL019 cells/kg (0.2 to 4). Among 29 patients reaching D28 prior to the data cutoff, 83% (24/29) achieved CR or CRi by local investigator assessment, all of which were MRD-negative. Two early deaths occurred prior to initial disease assessment, one due to disease progression and one due to intracranial hemorrhage. Two patients did not respond. One patient was in CR by BM at D28, but CSF was not assessed, therefore this patient was classified as "incomplete" assessment. Safety was managed by a protocol-specified CRS algorithm with no cases of refractory CRS. Using the Penn CRS grading scale, 82% of patients experienced CRS, with 7 grade 3 (21%) and 8 grade 4 (24%) events. 44% patients with CRS required anti-cytokine therapy; all received tocilizumab with or without other anti-cytokine therapy, with complete resolution of CRS. Besides CRS, the most common grade 3 and 4 non-hematologic AEs were febrile neutropenia (29%), increased bilirubin (21%), increased AST (21%), and hypotension (21%). 21% of patients experienced grade 3 or 4 neuropsychiatric events including confusion, delirium, encephalopathy, agitation and seizure; no cerebral edema was reported. CTL019 in vivo cellular kinetics by qPCR demonstrated transgene persistence in blood in responding patients at and beyond 6 months. Overall exposure (AUC 0-28d) and maximal expansion (Cmax) of CTL019 DNA measured by qPCR was higher in responding compared with non-responding patients. In summary, this pivotal global study in pediatric and young adult patients with r/r B-ALL receiving CTL019, confirms a high level of efficacy and a similar safety profile to that shown in the prior single center experience. Safety was effectively and reproducibly managed by appropriately trained investigators. The study has completed accrual. At the meeting, updated data from a planned formal interim analysis including safety, efficacy (primary and selected secondary endpoints), cellular kinetics, and impact of anti-cytokine therapy will be presented for more than 50 patients infused at 25 global sites. Disclosures Grupp: Jazz Pharmaceuticals: Consultancy; Novartis: Consultancy, Research Funding; Pfizer: Consultancy. Laetsch:Novartis: Consultancy; Loxo Oncology: Consultancy. Bittencourt:Seattle Genetics: Consultancy; Jazz Pharmaceuticals: Consultancy, Other: Educational Grant. Maude:Novartis: Consultancy. Myers:Novartis Pharmaceuticals: Consultancy. Rives:Novartis: Consultancy; Jazz Pharma: Consultancy. Nemecek:Medac, GmbH: Research Funding; Novartis: Consultancy; National Marrow Donor Program: Membership on an entity's Board of Directors or advisory committees. Schlis:Novartis: Honoraria. Martin:Jazz Pharmaceuticals: Other: One time discussion panel; Novartis: Other: Support of clinical trials. Bader:Medac: Consultancy, Research Funding; Riemser: Research Funding; Neovii Biotech: Research Funding; Servier: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Peters:Novartis: Consultancy; Jazz: Speakers Bureau; Amgen: Consultancy; Pfizer: Consultancy; Medac: Consultancy. Biondi:Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Cellgene: Other: Advisory Board; BMS: Membership on an entity's Board of Directors or advisory committees. Baruchel:Servier: Consultancy; Novartis: Consultancy; Celgene: Consultancy; Jazz: Consultancy; Baxalta: Research Funding. June:University of Pennsylvania: Patents & Royalties; Johnson & Johnson: Research Funding; Celldex: Consultancy, Equity Ownership; Pfizer: Honoraria; Immune Design: Consultancy, Equity Ownership; Novartis: Honoraria, Patents & Royalties: Immunology, Research Funding; Tmunity: Equity Ownership, Other: Founder, stockholder . Sen:Novartis: Employment. Zhang:Novartis: Employment. Thudium:Novartis: Employment. Wood:Novartis Pharmaceuticals: Employment, Other: Stock. Taran:Novartis: Employment. Pulsipher:Chimerix: Consultancy; Jazz Pharmaceutical: Consultancy; Novartis: Consultancy, Other: Study Steering Committee; Medac: Other: Housing support for conference.
44
"Industry Watch." Asia-Pacific Biotech News 11, no. 02 (2007): 90–104. http://dx.doi.org/10.1142/s0219030307000109.
Full textAbstract:
Millipore's HEScGRO Medium Advances Human Embryonic Stem Cell Research. A TCM Specialist — Beijing Tongrentang Co Ltd. Diagnostics Firm Adaltis to Acquire Shanghai Hua Tai Biotechnology. Organon Acquires Stake in HUYA to Develop Chinese Biopharmaceuticals. Renhuang Pharmaceuticals Received Major Order from Anhui Huayuan Pharmaceutical. Sinovac Biotech Ltd—A Leading Chinese Biotech Company. Skystar Bio-Pharmaceutical Signs Letter of Intent for Joint Scientific Research Project with TNI-Penta. Boston Scientific's Reports on Major Adverse Events of TAXUS Stent Study in Diabetic Patients. AsiaPharm Acquires Nanjing-based Pharmaceutical Group. DSM Biologics and Crucell Announced Licensing Agreement with AbGenomics Corporation. Grant Life Sciences Signs Collaboration Agreement with Taiwan's UCL for Diagnostic Products Validation. ScinoPharm Launches More Cancer Treatment APIs.
45
"STATE BIOTECHNOLOGY & PHARMACEUTICAL INDUSTRY BASE." Asia-Pacific Biotech News 07, no. 05 (2003): 192–93. http://dx.doi.org/10.1142/s0219030303000442.
Full text
46
"INSIDE INDUSTRY." Asia-Pacific Biotech News 15, no. 12 (2011): 37–42. http://dx.doi.org/10.1142/s0219030311000747.
Full textAbstract:
AtCor Signs US$0.9 Million Pharmaceutical Contract. Corning Opens Life Sciences Manufacturing and Distribution Facility in China. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology. GVK Biosciences Partners with PROOF Centre of Excellence. Stemade Biotech Unveils Dental Stem Cell Banking in Chandigarh. Israeli Firm to Hold Schizophrenia Clinical Trial in India. Quintiles and Prodia Partner to Provide Central Lab Testing Solution in Indonesia. Medtronic Begins Transcatheter Aortic Valve Trial in Japan. Intellect Neurosciences Obtains Two New Patents in Japan for Alzheimer's Immunotherapy Programs. ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Oncology Partnership.
47
"INSIDE INDUSTRY." Asia-Pacific Biotech News 22, no. 05 (2018): 36–40. http://dx.doi.org/10.1142/s021903031800037x.
Full textAbstract:
Drugs to watch 2018 First Pharmaceutical Regulation Graduate Certificate programme offered by Duke-NUS CoRE Evonik intensifies research into regenerative medicine SGInnovate completes investment in deep tech startup NDR Medical Technology Australian biotech AdAlta makes improvements to lung fibrosis drug AI and blockchain will counteract unsustainability of soaring drug prices Availability of orphan medicines varies between European countries
48
"Industry Watch." Asia-Pacific Biotech News 14, no. 02 (2010): 21–35. http://dx.doi.org/10.1142/s0219030310000108.
Full textAbstract:
Patrys to Work with CSL to Explore Antibody Drugs. Starpharma and Lilly Sign New Drug Delivery Collaboration for Human Pharmaceuticals. Sanofi, Minsheng in China Consumer Health Venture. Biocon Signs MoU with Malaysia's BiotechCorp. Biocon, Bayer Tie up to Fight Diabetes in India. Ranbaxy to Acquire Bangalore Based Biovel Life Sciences. DiscoveRx, Jubilant Biosys Announce Agreement for Screening Services. BD Biosciences Collaborates with ReaMetrix to Develop New, Affordable CD4 Testing Products to Help Fight HIV/AIDS in Developing Countries. Aegis Therapeutics and Dr. Reddy's Announce Strategic Alliance. Penwest Enters Into Research and Development Agreement with Otsuka Pharmaceutical. AstraZeneca and CrystalGenomics Form Research Collaboration to Develop Novel Anti-Infective Treatments. International and Local Recognition for Singaporean Biotech Start-up – Curiox Biosystems. Roche Establishes New Medical Research Hub in Singapore. Virbac Unveils First Regional R&D Center in Asia.
49
"INSIDE INDUSTRY." Asia-Pacific Biotech News 17, no. 01 (2013): 46–51. http://dx.doi.org/10.1142/s0219030313000074.
Full textAbstract:
Thermo Fisher Scientific and Applikon Biotechnology sign bilateral supply agreement. AET BioTech and BioXpress Therapeutics to co-develop biosimilar Adalimumab. Octa Phillip Bioscience Managers announces first close on new healthcare fund. Agilent Technologies' and PREMIER Biosoft's platforms work together to advance lipidomics research. Phosphagenics licenses TPM® platform to Indian pharmaceutical company. Dr. Louis-Philippe Vézina, named as a recipient of the 2012 Prix du Quebec.
50
Chakir lamrani, Houda. "Strategic Alliances and Financial Performance: Some Empirical Evidence of Bio-Pharmaceutical Industry." International Journal of Scientific Research and Management 7, no. 12 (2019). http://dx.doi.org/10.18535/ijsrm/v7i12.em04.
Full textAbstract:
Over the last decades, strategic alliance have played an important role among high tech firms, including biotech and pharmaceutical companies, showing an impact on financial performance. This study focuses on this topic and analyses how strategic alliances portfolios and types of the partnerships affect bio-pharmaceutical companies’ financial performances. Drawing upon a panel data set of 158 alliances during the period of 2003-2013, empirical findings highlight that the number of alliances has a negative relationship with financial performance, whereas partnership types such as licensing and co-development have a positive relationship with the financial performance of biotech and pharmaceutical companies.